Skip to content

Ovarian Cancer Cell Invasion and Metastasis: The Role of Mesothelial Cells

Ovarian cancer is a type of cancer that begins in the ovaries, the female reproductive glands responsible for producing...

Estimated reading time: 6 minutes

Ovarian cancer remains one of the most lethal gynaecological malignancies worldwide, partly because it can spread rapidly through the peritoneal cavity. In this process, cancer cells interact with other cells in their surroundings. A recent study published in Science Advances in 2026 sheds new light on this mechanism. Specifically, researchers found that mesothelial cells—which line the peritoneal cavity—can actively promote cancer progression. When they interact with ovarian cancer cells, they help form spheroids, or three-dimensional cell clusters. As a result, these clusters may invade surrounding tissue and spread more effectively. Thus, the findings challenge the view that mesothelial cells act only as a protective barrier. Moreover, they suggest that disrupting these interactions could offer new directions for treatment research. Ultimately, understanding how these cells work together may help researchers develop improved strategies for managing ovarian cancer.

Key Takeaways

  • Mesothelial cells play an active role in promoting ovarian cancer cell invasion, not just acting as a passive barrier
  • Spheroid formation represents a critical step in peritoneal metastasis of ovarian cancer
  • Targeting the molecular interactions between mesothelial and cancer cells could lead to new therapies
  • The study provides mechanistic insights that may improve prognostic assessments
  • Understanding spheroid biology helps explain chemotherapy resistance in ovarian cancer

The Peritoneal Environment and Ovarian Cancer Metastasis

The peritoneal cavity, therefore, presents a unique microenvironment for cancer spread. Ovarian cancer cells often detach from the primary tumor. Consequently, these cells float freely in the peritoneal fluid. Moreover, ascites frequently accompanies advanced disease. This fluid contains a mixture of cancer cells, immune cells, and mesothelial cells. To identify the key players, we must first consider the mesothelium. It lines the peritoneal cavity as a protective layer. Initially, most researchers viewed it as a simple barrier against cancer invasion. However, recent evidence suggests otherwise. Mesothelial cells, in fact, actively participate in cancer progression. They secrete growth factors and extracellular matrix components. As a result, these substances significantly influence cancer cell behavior.

The study by researchers at various institutions further demonstrates this active role. To observe cell interactions, they used advanced imaging techniques. The team found that mesothelial cells facilitate ovarian cancer cell invasion into the peritoneal wall. This process begins with spheroid formation: cancer cells aggregate into clusters, while mesothelial cells surround them. Together, these cells create a cooperative structure. Subsequently, this structure migrates and invades tissues. In other words, mesothelial cells become partners in crime rather than guardians. Thus, this finding fundamentally shifts our understanding of peritoneal metastasis.

How Mesothelial Cells Promote Spheroid Formation

Mesothelial Cells
Fig. 1: Mesothelial cells support ovarian cancer spheroids, helping them resist chemotherapy and recur.

Spheroid formation involves several coordinated steps. First, cancer cells detach from the primary tumor and enter the ascitic fluid. Although this fluid environment can normally trigger cell death, ovarian cancer cells adapt and activate survival pathways. In addition, mesothelial cells can enhance this adaptation by secreting hyaluronan and other extracellular matrix components. These molecules not only provide structural support but also activate signaling pathways in cancer cells. As a result, stable spheroids can form.

Cellular componentRole in spheroid formation
Ovarian cancer cellsForm the core of spheroids
Mesothelial cellsSurround and support spheroids
Extracellular matrixProvides a structural framework
Growth factorsPromote cell survival and proliferation

Once formed, spheroids exhibit distinctive properties. For example, they can resist chemotherapy better than individual cells, partly because their three-dimensional structure limits drug penetration. Furthermore, spheroid cells undergo metabolic changes and rely more heavily on oxidative phosphorylation. Consequently, they may be less susceptible to certain drugs. In particular, conventional platinum-based therapies can be less effective against spheroid cells. This may help explain why ovarian cancer often returns after initial treatment. In effect, spheroids can act as reservoirs of resistant cells: they may remain dormant for months or years and then reactivate, contributing to recurrent disease.

Molecular Mechanisms of Mesothelial-Cancer Cell Interactions

The study found that cells use certain signals to help cancer spread. One important signal uses integrins. Integrins are tiny parts on a cell’s surface. They help cells attach to the material around them. Mesothelial cells have integrins that can stick to proteins on cancer cells. This can send signals inside the cancer cells. These signals help the cells move and enter nearby tissue.

Another signal involves TGF-β, a substance made by mesothelial cells. TGF-β can change cancer cells through a process called EMT. After this change, cancer cells can move and spread more easily. They may also form groups called spheroids more easily.

Implications for Therapeutic Targeting

This finding may suggest new ways to treat ovarian cancer. Most current treatments try to kill cancer cells. They may not target the cells and material around the tumor. So, treating mesothelial cells as well could add to current care.

The study suggests several ideas to test:

Treatment ideaWhat it might do
Integrin blockersStop cancer cells from sticking to nearby cells
TGF-β blockersStop signals that help cancer cells change and spread
Hyaluronan-breaking enzymesBreak down the material around cancer cell groups
Metabolism-blocking drugsTarget how cancer cell groups make and use energy
Immune treatmentsHelp immune cells reach cancer cell groups

Using more than one treatment may work better than using just one. For example, blocking integrins along with chemotherapy might make cancer cells easier to treat. Breaking up cancer cell groups could also leave the cells less protected. However, these ideas need more testing. Future trials could study whether these methods help patients.

It will also be important to see which patients might benefit. Ovarian cancers can behave in different ways. Tests that show how active mesothelial cells are may help doctors choose treatments. The study points to possible signs for future research.

Frequently Asked Questions

What are mesothelial cells?

Mesothelial cells line body cavities, including the peritoneum. Normally, they provide a protective barrier; moreover, they secrete lubricating fluid. However, in ovarian cancer, they help cancer cells spread.

How does spheroid formation contribute to chemotherapy resistance? 

Spheroids have a three-dimensional structure. Thus, drug penetration is limited. Meanwhile, cells inside spheroids undergo metabolic changes. Consequently, they become less sensitive to chemotherapy drugs.

How soon might these findings affect patient care? 

Clinical applications require several years. First, preclinical studies must confirm safety. Then clinical trials must demonstrate efficacy. However, some drugs targeting these pathways already exist. They could be tested sooner.

References

Uno, K., Yoshihara, M., Yamakita, Y., Kitami, K., Iyoshi, S., Sugiyama, M., Koya, Y., Kanayama, T., Sahara, H., Nomura, S., Mogi, K., Miyamoto, E., Fujimoto, H., Yoshida, K., Tamauchi, S., Yokoi, A., Yoshikawa, N., Niimi, K., Shiraki, Y., … Kajiyama, H. (2024). Mesothelial cells promote peritoneal invasion and metastasis of ascites-derived ovarian cancer cells through spheroid formation. Science Advances, 10(28), eadu5944. https://doi.org/10.1126/sciadv.adu5944

Disclaimer.